What We're Reading: Page 313
Industry reads hand-picked by our editors
Jan 04, 2017
-
Forbes
30 under 30 in science 2017: Discovering new things about our world and new ways to save it
-
Bloomberg
Ono Pharma's wild 2016 ride cuts stock valuation by $16 billion
-
Health Affairs
Germany's model for drug price regulation could work in the US
-
The Boston Globe
Doctors are cutting opioids, even if it harms patients
-
Medical Marketing & Media
Pharma adopts data-science culture in move toward AI
Jan 03, 2017
-
Bloomberg
This army vet is fighting hep C with big pharma's help
-
The New York Times
National biotechnology panel faces new conflict of interest questions
-
BloombergGadfly
Biotech's back-to-the-future experiment
-
Reuters
Life-extending capacity of new cancer drugs varies widely
Jan 02, 2017
-
MIT Technology Review
Everything you need to know about gene therapy's most promising year
-
Bloomberg Gadfly
Brent Saunders's new model will be tested in 2017
-
Reuters
New drug approvals fall to six-year low in 2016
-
Forbes
Five 'big idea' biotech trends to watch in 2017
Dec 23, 2016
-
The Washington Post
Drug industry hired dozens of officials from the DEA as the agency tried to curb opioid abuse
-
The Wall Street Journal
Donald Trump's pick for Health Secretary traded medical stocks while in House
-
Nature
Fatal French clinical trial failed to check data before raising drug dose
-
Bloomberg
Martin Shkreli says ‘of course’ he’d raise drug price again
Dec 22, 2016
Dec 21, 2016
-
The New York Times
Senate aims to stop firms from ‘buying up drugs and jacking up prices’
-
Reuters
Sanofi's takeover talks with Actelion progressing: source
-
The News & Observer
Triangle biotech businesses big winners under new medical research law
-
BloombergGadfly
Biogen's a tough gig for any CEO
Dec 20, 2016
-
The New York Times
Harnessing the U.S. taxpayer to fight cancer and make profits
-
Los Angeles Times
Soaring insulin prices highlight futility of 'free market' for meds
-
Fortune
Here's why investors weren't excited about Biogen's new CEO
-
The Hill
Drugmakers await FDA guidance on 'off-label' uses of medicines
Previous
